Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing Agreement

Published: Thursday, April 24, 2014
Last Updated: Thursday, April 24, 2014
Bookmark and Share
Samsung will manufacture commercial drug substances and drug product at Incheon manufacturing site.

Bristol-Myers Squibb Company and Samsung BioLogics have announced that the companies will increase the scope of their existing manufacturing agreement in which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at its Incheon manufacturing site. Financial terms of the agreement are not disclosed.

Bristol-Myers Squibb and Samsung announced their first manufacturing agreement in July 2013 to collaborate in the production of a single commercial antibody cancer drug substance.

"Biologic medicines that treat serious diseases are an integral part of Bristol-Myers Squibb’s specialty care portfolio and R&D pipeline,” said Lou Schmukler, president, Global Manufacturing & Supply. “The expanded relationship with Samsung will increase our biologics manufacturing capability and give us the flexibility to respond to increased demand in order to meet the global needs of patients.”

"Samsung is delighted to reach the second manufacturing agreement with Bristol-Myers Squibb and we look forward to delivering top quality GMP production," said Dr. TH Kim, president and CEO of Samsung BioLogics. “It represents another significant step for Samsung and Bristol-Myers Squibb in strengthening our biopharmaceutical manufacturing relationship.”

Samsung brings global biopharmaceutical capability through its fully-integrated production facilities that offer process development, drug substance manufacturing, and drug product fill & finish services at one location.

In addition to its current biologics manufacturing facility in Incheon, Korea, the company is currently building a second facility, also in Incheon, which is expected to be completed in early 2015.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BMS and Moffitt Cancer Center Enter Into a Collaboration Agreement
Agreement as part of U.S. Immuno-Oncology Rare Population Malignancy program.
Saturday, October 03, 2015
Bristol-Myers Squibb Enters Agreement Providing Exclusive Right to Acquire Promedior
BMS will gain worldwide rights to Promediors lead asset PRM-151, a recombinant form of human pentraxin-2 protein in Phase 2 development for the treatment of idiopathic pulmonary fibrosis (IPF) and myelofibrosis
Monday, September 07, 2015
Bristol-Myers Squibb and Promedior Enters into Agreement
Agreement providing exclusive right to acquire Promedior, Inc. and its novel PRM-151 in development for fibrotic diseases.
Thursday, September 03, 2015
BMS Partners with Medical University
The Medical University of South Carolina and Bristol-Myers Squibb Company have announced that they have entered into a collaboration focused on fibrotic diseases, including scleroderma, renal fibrosis and idiopathic pulmonary fibrosis.
Thursday, July 16, 2015
Bristol-Myers Squibb and uniQure Enter into Strategic Collaboration
Collaboration to develop gene therapies for cardiovascular diseases.
Thursday, April 09, 2015
Bristol-Myers Squibb to Expand its Immuno-Oncology Pipeline
Gains full rights to Flexus’ lead preclinical IDO1 inhibitor F001287 and the company’s broad IDO/TDO discovery program.
Thursday, February 26, 2015
Bristol-Myers Squibb and Calibr Collaborate
Collaboration and license agreement focused on new treatment approaches for fibrotic diseases.
Thursday, January 08, 2015
BMS to Construct a New Large-Scale Biologics Manufacturing Facility in Ireland
Facility will produce multiple therapies for the company’s growing biologics portfolio.
Tuesday, November 25, 2014
Bristol-Myers Squibb and Lonza Expand Manufacturing Agreement
Contract expansion will include the production of commercial quantities of a second BMS biologic medicine at Lonza’s Portsmouth facility.
Friday, November 07, 2014
Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration
Collaboration to evaluate OPDIVO® (nivolumab) and IMBRUVICA®(ibrutinib) in non-Hodgkin lymphoma.
Thursday, October 16, 2014
Bristol-Myers Squibb and Celgene Enter Clinical Collaboration Agreement
Phase I study to evaluate OPDIVO (nivolumab), Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, with Celgene’s ABRAXANE® for multiple cancers.
Thursday, August 21, 2014
B-MS, Ono Pharmaceutical Announce Immuno-Oncology Collaboration
Companies to develop and commercialize multiple immunotherapies to help address the unmet medical needs of patients with cancer in Japan, South Korea and Taiwan.
Thursday, July 24, 2014
B-MS, Syngene Extend Research Collaboration
Companies announce a five-year extension of their drug discovery and development collaboration in India.
Wednesday, June 04, 2014
FDA Grants Breakthrough Designation for Multiple Myeloma Drug
Bristol-Myers Squibb and AbbVie received the designation for Elotuzumab, an investigational humanized monoclonal antibody for multiple myeloma.
Tuesday, May 20, 2014
Bristol-Myers Squibb Acquires iPierian
B-MS acquires iPierian, a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies, for $175M.
Thursday, May 01, 2014
Scientific News
13 Ways to Stop an Unseen Force from Disrupting Weighing
Download a free Mettler Toledo paper to discover how to halt static’s negative effects before the next weigh-in.
Flinders Ig Nobel Winner Cracks Global Anaesthetic
One of the world’s most in-demand anaesthetics can now be produced on the spot, thanks to the thermos-flask sized device that recently won Flinders University inventor Professor Colin Raston an Ig Nobel prize.
Resurrected Proteins Double Their Natural Activity
Researchers demonstrate method for reviving denatured proteins.
Genes That Protect African Children From Developing Malaria Identified
Variations in DNA at a specific location on the genome that protect African children from developing severe malaria, in some cases nearly halving a child’s chance of developing the life-threatening disease, have been identified in the largest genetic association study of malaria to date.
Messing With The Monsoon
Manmade aerosols can alter rainfall in the world’s most populous region.
Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Scientists Decode Structure at Root of Muscular Disease
Researchers at Rice University and Baylor College of Medicine have unlocked the structural details of a protein seen as key to treating a neuromuscular disease.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
New Test Detects All Viruses
A new test detects virtually any virus that infects people and animals, according to research at Washington University School of Medicine in St. Louis, where the technology was developed.
Inroads Against Leukemia
Potential for halting disease in molecule isolated from sea sponges.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos